Human Rotavirus Vaccine Market 2018-2023 | Anticipated Constant Growth at CAGR of 11.2% with Prestigious Players as Bharat Biotech, Merck & Co. Inc., GlaxoSmithKline plc., Sanofi etc.

Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Symptoms of rotavirus infection include severe diarrhoea, vomiting, fever, and abdominal pain which can result in disease. Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available in the United States in 2006.

Click to Get Sample Report @ https://www.marketresearchfuture.com/sample_request/4171 .

Rotavirus is a double-stranded RNA virus of the family Reoviridae and is transmitted through the faecal-oral route. It infects the cell lining of the small intestine and causes gastroenteritis. According to National Center for Biotechnology Information, rotavirus related diarrhoea was responsible for killing about 600,000 children in 2015, with more than 80% of all rotavirus-related deaths occurring in in South Asia and sub-Saharan Africa. Rotavirus-related deaths represent approximately 5% of all deaths in children younger than 5 years of age worldwide. Almost every child in the world is infected with rotavirus at least once by the age of five. The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs. The vaccines is responsible to prevent 15 to 34% of severe diarrhoea in the developing world and 37 to 96% of severe diarrhoea in the developed world. According to World Health Organization (WHO) in Mexico a decline of up to 50% in diarrhoeal deaths in children less than 5 years of age was attributed directly to the use of the vaccine.

The market drivers for rotavirus vaccine market are its safety profile including use in HIV/AIDS patients, growing number of immunity-compromised individuals, increasing geriatric population, growing population and live births etc. The market restraints are risks such as immune reaction, babies who have had intussusception, low healthcare expenditure in developing regions, cleanliness initiatives by NGOs and health awareness creation to eradicate the prevalence of this virus etc.

The global human rotavirus vaccine market is expected to reach US$ 12.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 11.2 % during the forecast period 2017-2023.

Global Human Rotavirus Vaccine Market – Key Players

Key players profiled in the report are:

Bharat Biotech
Merck & Co. Inc.
GlaxoSmithKline plc
Sanofi

Global Human Rotavirus Vaccine Market – Regional Analysis

The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global human rotavirus vaccine market. Also, concentration of major research companies and vaccine research sector in the developed countries of this region is adding fuel to the market growth.

Europe is the second largest market in the world due to high income and healthcare penetration.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Get Discount on Report @ https://www.marketresearchfuture.com/check-discount/4171 .

Global Human Rotavirus Vaccine Market - Competitive Analysis

There are majorly three pharmaceutical companies licensed for rotavirus vaccines, Rotarix that is manufactured by GlaxoSmithKline Biologicals and RotaTeq manufactured by Merck & Co. Inc., a U.S. based company challenging these two major companies an Indian pharmaceutical company Bharat Biotech launched the lowest price rotavirus vaccine named Rotavac. There are various companies are seeking interest in manufacturing of these vaccine due low presence of manufacturers. New necessities for the development, manufacturing and licensure of new vaccine candidates have caused a marked rise in manufacturers’ investment costs. To compensate these investments in research and development and engender profits while the manufacturer monopolizes the market.

The company GlaxoSmithKline has offered to deliver this vaccine at price of US$ 2.50 every dose, which creates a 67% decrease over the lowest public price now available. Merck & Co. Inc. has offered to deliver the vaccine at price of US$ 3.5 every dose once the volume of purchase reaches 30 million doses. Although in 2011 there Indian company Bharat Biotech, announced the cost of its vaccine challenging GSK, Merck in the market. With its product Rotavac vaccine, the company quoted the lowest price i.e. 60 rupees that is less than 1$ for three doses of rotavirus vaccine.

The successful launch of this products by Bharat Biotech brought an end to the products research and development since 1985. The company with the help of various institutes like PATH, NIH, CDC and the Stanford University School of Medicine made it possible for the successfully launch of the product. In 2015 the company raised a fund of about $20 million for constructing new facilities and supporting infrastructure at its Genome Valley plant. With this development in its infrastructure the company is expected to generate a capacity of 300 million doses every year. Due to this developments the company lead the market in India and gradually across the world.

Global Human Rotavirus Vaccine Market – Segmentation

The global Human rotavirus vaccine market has been segmented on the basis of type and end users.

Based on type, the market has been segmented as Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb and others.

Based on the end users, the market has been segmented as hospitals & clinics, academic and research and others.

Ask to an Expert @ https://www.marketresearchfuture.com/enquiry/4171 .

Major Table of Contents

1. Introduction
1.1 Definition

1.2 Scope of Study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure

2. Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators

4. Market Factor Analysis

Continued….

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.